Virtus ETF Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-17,361
| Closed | -$343K | – | 484 |
|
|
2024
Q4 | $343K | Sell |
17,361
-195
| -1% | -$3.86K | 0.14% | 208 |
|
|
2024
Q3 | $439K | Hold |
17,556
| – | – | 0.21% | 192 |
|
|
2024
Q2 | $328K | Sell |
17,556
-4,791
| -21% | -$89.4K | 0.16% | 213 |
|
|
2024
Q1 | $441K | Buy |
22,347
+3,215
| +17% | +$63.4K | 0.23% | 186 |
|
|
2023
Q4 | $336K | Buy |
19,132
+671
| +4% | +$11.8K | 0.21% | 199 |
|
|
2023
Q3 | $321K | Sell |
18,461
-2,390
| -11% | -$41.5K | 0.19% | 196 |
|
|
2023
Q2 | $294K | Buy |
20,851
+1,155
| +6% | +$16.3K | 0.17% | 211 |
|
|
2023
Q1 | $212K | Buy |
19,696
+351
| +2% | +$3.78K | 0.12% | 304 |
|
|
2022
Q4 | $290K | Sell |
19,345
-9,062
| -32% | -$136K | 0.15% | 287 |
|
|
2022
Q3 | $365K | Buy |
28,407
+415
| +1% | +$5.33K | 0.15% | 244 |
|
|
2022
Q2 | $271K | Sell |
27,992
-2,029
| -7% | -$19.6K | 0.1% | 278 |
|
|
2022
Q1 | $298K | Hold |
30,021
| – | – | 0.13% | 177 |
|
|
2021
Q4 | $353K | Buy |
30,021
+12
| +0% | +$141 | 0.13% | 181 |
|
|
2021
Q3 | $342K | Sell |
30,009
-2,753
| -8% | -$31.4K | 0.15% | 187 |
|
|
2021
Q2 | $456K | Buy |
32,762
+17,348
| +113% | +$241K | 0.19% | 179 |
|
|
2021
Q1 | $285K | Buy |
15,414
+266
| +2% | +$4.92K | 0.12% | 250 |
|
|
2020
Q4 | $268K | Buy |
15,148
+831
| +6% | +$14.7K | 0.11% | 285 |
|
|
2020
Q3 | $219K | Sell |
14,317
-1,957
| -12% | -$29.9K | 0.11% | 286 |
|
|
2020
Q2 | $415K | Buy |
+16,274
| New | +$415K | 0.2% | 186 |
|
|
2019
Q2 | – | Sell |
-11,763
| Closed | -$212K | – | 443 |
|
|
2019
Q1 | $212K | Sell |
11,763
-1,773
| -13% | -$32K | 0.45% | 86 |
|
|
2018
Q4 | $380K | Buy |
+13,536
| New | +$380K | 0.06% | 83 |
|